Aperiomics to present at Cavendish Global Health Impact Forum
Friday, May 5, 2017
Virginia Bio member, Aperiomics, a biotech company that has created a unique technology to revolutionize the diagnosis of infectious disease, has been selected to present at the Cavendish Global Health Impact Forum taking place May 7-9, 2017 in Washington, DC, co-hosted with the Virginia Biotechnology Association (VirginiaBio). The Forum provides an environment for family offices, foundations and impact investors develop and implement their individual pro-social impact investing, grant-giving, and philanthropy programs within health and the life sciences. To accomplish this mission, the Forum showcases presentations and panel discussions by leading family offices, accomplished foundations, impact investors, research institutions, private-sector companies and nonprofit organizations engaged in developing innovations with the potential for transformational impact on disease prevention, diagnosis and treatment. A unique gathering of impact investors, Cavendish Impact Forums are hosted by leading institutions around the world and take place four times each year.
Michael Moffat, Cavendish co-founder and Chairman explains, “With the help of our expert advisors, we conduct a global search of research institutions and private-sector companies in order to identify organizations that meet the required standard of excellence. The quality and originality of Aperiomics’ research and scientific insights in the diagnosis of infectious disease positions them to make a major contribution in creating better clinical outcomes, preventing and containing epidemics, and limiting the development of antibiotic-resistant “super bugs”.
“We are honored to be selected to present at this unique event, and it is further recognition of our innovative approach to quickly and accurately identify any known pathogen from a single test. The effects of this novel technology will be felt around the world as health care providers are enabled to quickly diagnose and properly treat diseases afflicting human and animal populations around the world,” said Crystal Icenhour, PhD and CEO of Aperiomics and Virginia Bio Chariman. “We welcome the chance to interact with many of the world’s most accomplished scientists, thought-leaders and generous philanthropic individuals and families who are all dedicated to the common cause of improving the health and lives of people around the world.”
Cavendish Global consists of over 200 leading family offices, foundations and impact investors from around the world with combined assets of over $225 billion who share a passion for pro-social endeavors within health and the life sciences. The Cavendish Global Health Impact Forum provides impact investors with a discrete, peer-to-peer knowledge expansion and relationship building environment, combined with the information and educational resources required by foundations actively seeking to accelerate technological innovation and health access through sustainable philanthropy, grant-making and impact investing. The Forum is also an opportunity for impact investors to champion and share information on projects and organizations, which they are passionate about with other impact investors from around the world.